Bliss GVS Pharma Limited (NSE:BLISSGVS)

Market Cap	68.84B +408.7%
Revenue (ttm)	10.74B +24.9%
Net Income	1.61B +47.0%
EPS	14.88 +44.2%
Shares Out	n/a
PE Ratio	43.74
Forward PE	n/a
Dividend	1.50 (0.23%)
Ex-Dividend Date	Jul 8, 2026

Volume	103,491
Open	655.50
Previous Close	654.75
Day's Range	633.00 - 667.00
52-Week Range	140.80 - 739.90
Beta	1.20
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About Bliss GVS Pharma

Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. The company offers anti-diabetic, anti-infective, anti-inflammatory, antifungal, antihemorrhoidal, antimalarial, antiseptic, cardiovascular, dermatological, gastrointestinal, gynaecology, neoro/cns, ophthalmic, otc drugs, respiratory, urology, and supplementary drug products, as well as engages in pain management services. It exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is b...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 1,033
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BLISSGVS

Financial Performance

In fiscal year 2026, Bliss GVS Pharma's revenue was 9.27 billion, an increase of 14.50% compared to the previous year's 8.10 billion. Earnings were 1.29 billion, an increase of 53.18%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error